Leder av Pediatric Follow-up Group ved Universitetet i Bergen og Klinisk forskningspost for barn og unge ved Haukeland universitetssykehus.

Hennes forskning er spesielt fokusert på nyremedisin, immunologi og kliniske utprøvingsstudier. Som del av NorCRIN (siden 2012) og NorPedMed (siden 2014) jobber hun for mer behandlingsforskning gjennomført i Norge. Hun er ECRINs norske vitenskapelige representant, leder barnenefrologisk interessegruppe i NBF og er nasjonal ESPN-kontakt.

Leder for utdanning, Klinisk institutt 2, Universitetet i Bergen

MED9: Pediatrisk nefrologi og reumatologi. Pediatrisk farmakologi. Generell pediatri. Væskebehandling hos barn. Forgiftninger hos barn. Sosialpediatri.

MED5: Kommunikasjon med barn og ungdom

GCP901: Kursleder. Kurs i kliniske utprøvingsstudier.

MEDMET1: ICH-Good Clinical Practice

NUCLI352: Pediatrisk nefrologi

 

Vitenskapelig artikkel

• Cristina Prat-Aymerich; Lusine Yeghiazaryan; Rishi Delan Pathirana et al. (2026). A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5–11 years old (CoVacc trial). (ekstern lenke)
• Oddvar Oppegaard; Bjørn Blomberg; Rebecca Jane Cox et al. (2026). Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial. (ekstern lenke)
• Hassan Osman Alhassan Elsaid; Jessica Furriol Palmer; Øystein Solberg Eikrem et al. (2026). Modeling Fabry nephropathy: insights from experimental systems towards precision nephrology. (ekstern lenke)
• Sindre Haukefer Hauan; Camilla H. Nundal; Sarah Larteley Lartey Jalloh et al. (2026). Analysing Antibodies Against Respiratory Viruses in Breast Milk: A Pilot Study. (ekstern lenke)
• Holida, Myrl; Linhart, Aleš; Longo, Nicola et al. (2026). Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study. (ekstern lenke)
• Camilla Tøndel; Synne Jenum; Kristian Tonby et al. (2026). SARS-CoV-2 T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial. (ekstern lenke)
• Camilla Tøndel; Uma Ramaswami; Kristin Moberg Aakre et al. (2009). Monitoring renal Function in Fabry children: comparisons of measured and creatinine-based estimated Glomerular Filtration Rate. (ekstern lenke)
• Rannveig Skrunes; Einar Svarstad; Kristin Kampevold Larsen et al. (2016). Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. (ekstern lenke)
• Antonio C Arrieta; Jocelyn Y Ang; Claudia Espinosa et al. (2021). Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age. (ekstern lenke)
• Lena Hansen; Karl Albert Brokstad; Amit Bansal et al. (2023). Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. (ekstern lenke)
• Frits Wijburg; Bernard Benichou; Daniel G Bichet et al. (2015). Characterization of early disease status in treatment-naive male paediatric patients with fabry disease enrolled in a randomized clinical trial. (ekstern lenke)
• Camilla Tøndel; Takahiro Kanai; Kristin Kampevold Larsen et al. (2015). Foot process effacement is an early marker of nephropathy in young classic fabry patients without albuminuria. (ekstern lenke)
• Camilla Tøndel; Leif Bostad; Kristin Kampevold Larsen et al. (2013). Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease. (ekstern lenke)
• Giacomo Casabona; Ahsan Habib; Michael Povey et al. (2021). Randomised controlled trial showed long-term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children. (ekstern lenke)
• John S Bradley; Nataliia Makieieva; Camilla Tøndel et al. (2023). Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial. (ekstern lenke)
• Nina Urke Ertesvåg; Julie Xiao; Fan Zhou et al. (2022). A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. (ekstern lenke)
• Bjørn Steinar Lillås; Camilla Tøndel; Anna Gjerde et al. (2019). Measurement of renal functional response using iohexol clearance-A study of different outpatient procedures. (ekstern lenke)
• Camilla Tøndel; Hans Peter Marti (2021). Cardiovascular changes in young renal failure patients. (ekstern lenke)
• Julian F Guest; Trond Jenssen; Gunnar Houge et al. (2010). Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion. (ekstern lenke)
• Einar Svarstad; Sabine Maria Leh; Rannveig Skrunes et al. (2017). Bedside stereomicroscopy of Fabry kidney biopsies: An easily available method for diagnosis and assessment of sphingolipid deposits. (ekstern lenke)
• Øystein Solberg Eikrem; Rannveig Skrunes; Camilla Tøndel et al. (2017). Pathomechanisms of renal Fabry disease. (ekstern lenke)
• Camilla Tøndel; Uma Ramaswami; Kristin Moberg Aakre et al. (2010). Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate. (ekstern lenke)
• Heidi Syre; Marius Eduardo Brå Obreque; Ingvild Dalen et al. (2022). The performances of three commercially available assays for the detection of SARS‐CoV‐2 antibodies at different time points following SARS‐CoV‐2 infection. (ekstern lenke)
• Sanne van der Veen; Simon Körver; A Hirsch et al. (2021). Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression. (ekstern lenke)
• Eric Wallace; Ozlem Goker-Alpan; William R Wilcox et al. (2023). Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: Results from the 2-year randomised phase III BALANCE study. (ekstern lenke)
• Gabor E. Linthorst; Allessandro Burlina; Franco Cecchi et al. (2012). Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage. (ekstern lenke)
• Camilla Tøndel; Bjørn Egil Vikse; Leif Bostad et al. (2012). Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. (ekstern lenke)
• Hassan Osman Alhassan Elsaid; Mariell Lossius Rivedal; Eleni Skandalou et al. (2023). Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla ^−/− zebrafish model of Fabry disease. (ekstern lenke)
• Kristin M. Aakre; Camilla Tøndel; Atle Brun et al. (2009). The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function. (ekstern lenke)
• Nicolas Delaleu; Hans Peter Marti; Philipp Strauss et al. (2023). Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing. (ekstern lenke)
• Aleš Linhart; Gabriela Dostalova; Kathy Nicholls et al. (2023). Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. (ekstern lenke)
• Linda van der Tol; David Cassiman; Gunnar Houge et al. (2014). Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. (ekstern lenke)
• Geir Bredholt; Marianne Sævik; Hanne Søyland et al. (2024). Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adults. (ekstern lenke)
• Mai Chi Trieu; Amit Bansal; Anders Madsen et al. (2020). SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. (ekstern lenke)
• Camilla Tøndel; Bjørn Johan Bolann; Cathrin Lytomt Salvador et al. (2016). Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times. (ekstern lenke)
• Behzad Najafian; Camilla Tøndel; Einar Svarstad et al. (2020). Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss. (ekstern lenke)
• Cathrin Lytomt Salvador; Camilla Tøndel; Lars Mørkrid et al. (2015). Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots. (ekstern lenke)
• Hassan Osman Alhassan Elsaid; Jessica Furriol; Maria Blomqvist et al. (2022). Reduced α-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype. (ekstern lenke)
• Thea Tislevoll Eide; Karl Ove Hufthammer; Atle Brun et al. (2021). Accuracy of single intravenous access iohexol GFR in children is hampered by marker contamination. (ekstern lenke)
• Bjørn Steinar Lillås; Camilla Tøndel; Jörg Assmus et al. (2021). Low birthweight is associated with lower glomerular filtration rate in middle-aged mainly healthy women. (ekstern lenke)
• Eefje B. Suntjens; Wouter Albert Dreschler; Jeanette Hess-Erga et al. (2017). Hearing loss in children with Fabry disease. (ekstern lenke)
• Elisabeth Berg Fjelltveit; Bjørn Blomberg; Kanika Kuwelker et al. (2022). Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. (ekstern lenke)
• Fabian Braun; Ahmed Abed; Dominik Sellung et al. (2023). Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy. (ekstern lenke)
• Einar Svarstad; Leif Bostad; Øyvind Kaarbøe et al. (2005). Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry's disease. (ekstern lenke)
• Michael Mauer; Emily Glynn; Einar Svarstad et al. (2014). Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. (ekstern lenke)
• Camilla Tøndel; Liv Marie Lægreid; Asle Hirth et al. (2003). [Intravenous Enzyme Substitution Therapy in Children With Fabry's Disease]. (ekstern lenke)
• Linda van der Tol; Einar Svarstad; Alberto Ortiz et al. (2014). Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. (ekstern lenke)
• Cathrin Lytomt Salvador; Per Trygge Kjelland Flemmen; Camilla Tøndel et al. (2023). Renal function, sex and age influence purines and pyrimidines in urine and could lead to diagnostic misinterpretation. (ekstern lenke)
• Cathrin Lytomt Salvador; Camilla Tøndel; Alexander D. Rowe et al. (2017). Renal Function Influences Diagnostic Markers in Serum and Urine: A Study of Guanidinoacetate, Creatine, Human Epididymis Protein 4, and Neutrophil Gelatinase–Associated Lipocalin in Children. (ekstern lenke)
• Amit Bansal; Mai Chi Trieu; Kristin Greve-Isdahl Mohn et al. (2023). Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers. (ekstern lenke)
• Petur Benedikt Juliusson; Camilla Tøndel; Sylvi Aanderud et al. (2002). Behandling av Graves sykdom hos barn og unge. (ekstern lenke)
• Hassan Osman Alhassan Elsaid; Håkon Tjeldnes; Mariell Lossius Rivedal et al. (2022). Gene Expression Analysis in gla-Mutant Zebrafish Reveals Enhanced Ca²⁺ Signaling Similar to Fabry Disease. (ekstern lenke)
• Behzad Najafian; Camilla Tøndel; Einar Svarstad et al. (2016). One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease. (ekstern lenke)
• Camilla Tøndel; Leif Bostad; Asle Hirth et al. (2008). Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. (ekstern lenke)
• Alessandro Burlina; Thomas Duning; Julian Fernandez-Martin et al. (2024). Fabry disease: current gaps and actionable solutions to improve Fabry patients’ clinical journey. (ekstern lenke)
• Myrl Holida; Aleš Linhart; Antonio Pisani et al. (2024). A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. (ekstern lenke)
• Ann Christin Gjerstad; Rannveig Skrunes; Camilla Tøndel et al. (2022). Kidney biopsy diagnosis in childhood in the Norwegian Kidney Biopsy Registry and the long-term risk of kidney replacement therapy: a 25-year follow-up. (ekstern lenke)
• David Moreno-Martinez; Patricio Aguiar; Christiane Auray-Blais et al. (2021). Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus. (ekstern lenke)
• Kristin Greve Isdahl Mohn; Karl Albert Brokstad; Shahinul Islam et al. (2020). Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children. (ekstern lenke)
• Kanika Kuwelker; Fan Zhou; Bjørn Blomberg et al. (2021). Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. (ekstern lenke)
• Małgorzata Baka‐Ostrowska; David T. Bolong; Cristian Persu et al. (2021). Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study. (ekstern lenke)
• Fan Zhou; Juha Vahokoski; Siri Øyen et al. (2024). Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection. (ekstern lenke)
• Kristin Greve Isdahl Mohn; Karl Albert Brokstad; Rishi Pathirana et al. (2016). Live attenuated influenza vaccine in children induces b-cell responses in tonsils. (ekstern lenke)
• Daniel G Bichet; Robert J. Hopkin; Patricio Aguiar et al. (2023). Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study. (ekstern lenke)
• Bjørn Steinar Demma Lillås; Camilla Tøndel; Toralf Melsom et al. (2023). Renal Functional Response-Association With Birth Weight and Kidney Volume. (ekstern lenke)
• Hjørdis Thorsteinsdottir; Cathrin Lytomt Salvador; Geir Mjøen et al. (2020). Growth Differentiation Factor 15 in Children with Chronic Kidney Disease and after Renal Transplantation. (ekstern lenke)
• Robert J. Hopkin; Ana Martins; Julia Alton et al. (2024). Plain Language Summary: Looking at treatment outcomes in people with Fabry disease who started agalsidase beta before the age of 30 years. (ekstern lenke)
• Robert J. Hopkin; Gustavo Cabrera; John Jefferies et al. (2022). Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry registry. (ekstern lenke)
• Kristin Greve Isdahl Mohn; Geir Bredholt; Karl Albert Brokstad et al. (2015). Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. (ekstern lenke)
• Bjørn Blomberg; Kristin Greve-Isdahl Mohn; Karl Albert Brokstad et al. (2021). Long COVID in a prospective cohort of home-isolated patients. (ekstern lenke)
• David Smerkous; Michael Mauer; Camilla Tøndel et al. (2023). Development of an automated estimation of foot process width using deep learning in kidney biopsies from patients with Fabry, minimal change, and diabetic kidney diseases.. (ekstern lenke)
• Christiane Lerche Sandbye; Rukshana Shroff; Mandy Wan et al. (2018). Effects of nutritional Vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease. (ekstern lenke)
• Rannveig Skrunes; Camilla Tøndel; Sabine Maria Leh et al. (2017). Long-term dose-dependent agalsidase effects on kidney histology in fabry disease. (ekstern lenke)
• Marieke Biegstraaten; R Arngrímsson; F Barbey et al. (2015). Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document. (ekstern lenke)
• Cathrin Lytomt Salvador; Camilla Tøndel; Alexander D. Rowe et al. (2018). Estimating glomerular filtration rate in children: evaluation of creatinine- and cystatin C-based equations. (ekstern lenke)
• Behzad Najafian; Aurelio Silvestroni; Alexey Sokolovskiy et al. (2022). A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease. (ekstern lenke)
• Camilla Tøndel; Cathrin Lytomt Salvador; Karl Ove Hufthammer et al. (2017). Iohexol plasma clearance in children: validation of multiple formulas and single-point sampling times. (ekstern lenke)
• Behzad Najafian; Einar Svarstad; Leif Bostad et al. (2011). Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. (ekstern lenke)
• Uma Ramaswami; Daniel G Bichet; Lorne Clarke et al. (2019). Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial. (ekstern lenke)
• Marco Spada; Ralf Baron; Perry M. Elliott et al. (2018). The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts. (ekstern lenke)
• Søren Rittig; Malgorzata Baka-Ostrowska; Camilla Tøndel et al. (2019). The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. (ekstern lenke)
• Nori JL Smeets; Esther MM Teunissen; Kim van der Velden et al. (2022). Glomerular filtration rate in critically ill neonates and children: creatinine-based estimations versus iohexol-based measurements. (ekstern lenke)

Medieintervju

• Camilla Tøndel (2025). Vil ha tidlig pottetrening: – Vi lærer ungene å tisse på seg. (ekstern lenke)
• Camilla Tøndel (2022). Nye behandlingsformer for Fabrys sykdom under utprøving. (ekstern lenke)
• Camilla Tøndel; Are Stuwitz Berg (2024). Vaksine mot vannkopper. (ekstern lenke)
• Camilla Tøndel (2024). Foreslår at alle barn skal få vaksine mot vannkopper fra neste år. (ekstern lenke)
• Camilla Tøndel (2021). Her settes første dose av norskutviklet koronavaksine. (ekstern lenke)
• Rebecca Jane Cox; Camilla Tøndel; Anne Spurkland et al. (2023). Bør alle norske barn vaksineres mot vannkopper?. (ekstern lenke)
• Camilla Tøndel (2013). Forskning på medisiner til barn, Ekko. (ekstern lenke)
• Camilla Tøndel (2024). Evolving screening and diagnosis strategies in Fabry disease. (ekstern lenke)
• Maria Winther Gunnes; Camilla Tøndel (2014). Kampen mot kreft. (ekstern lenke)
• Camilla Tøndel (2015). Har testet medisiner på 400 barn. (ekstern lenke)
• Camilla Tøndel (2015). Kreft hos barn og betydning av klinisk utprøving hos barn. (ekstern lenke)
• Camilla Tøndel (2022). Katrine (47) har meldt seg frivillig til å teste en ny, norsk vaksine. Håpet er at den skal beskytte lenger enn de man har hatt til nå. (ekstern lenke)
• Camilla Tøndel (2022). Lovende resultater av mulig ny behandling av Fabry sykdom: – Stor praktisk betydning. (ekstern lenke)
• Camilla Tøndel; Einar Svarstad (2013). Enzyme replacement in Fabry disease. (ekstern lenke)
• Thomas Halvorsen; Camilla Tøndel (2014). Forskning på legemidler til barn må gjøres i Norge. (ekstern lenke)

Konferanseabstrakt

• Robert Hopkin; F. Salomone; Derralynn A. Hughes et al. (2025). Évaluation de la relation entre les réactions liées à la perfusion et les anticorps antimédicament statut : résultats de 111 patients atteints de la maladie de Fabry traités par pegunigalsidase alfa. (ekstern lenke)
• John Bernat; F. Salomone; Myrl Holida et al. (2025). Prolongation de l’intervalle entre les perfusions de pégunigalsidase alfa chez les patients atteints de la maladie de Fabry : résultats intermédiaires sur cinq ans de l’étude BRIGHT51 en cours. (ekstern lenke)
• Frits Wijburg; Bernard Benichou; Daniel G Bichet et al. (2013). A randomized, multicenter, multinational, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms: Baseline demographics and clinical data. (ekstern lenke)
• Behzad Najafian; Chester Whitley; Beth Thurberg et al. (2013). Renal structural-functional relationship (SFR) studies suggest that podocyte GL-3 accumulation predicts urine protein creatinine ratio in Fabry disease (FD) nephropathy (FDN). (ekstern lenke)
• Behzad Najafian; Emily Glynn; Einar Svarstad et al. (2012). Mosaicism of Podocyte Involvement in Untreated Females with Fabry Disease. (ekstern lenke)
• Camilla Tøndel; Leif Bostad; Einar Svarstad (2010). RENAL FOLLOW-UP BIOPSIES IN YOUNG MALE FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY. (ekstern lenke)
• Camilla Tøndel; Anne Kjørsvik Bertelsen; Leif Bostad et al. (2009). Fabry Disease: Unusual Symptoms in two Boys Treated with Lamotrigine and Fabrazyme, Respectively. (ekstern lenke)
• Camilla Tøndel; Uma Ramaswami; Kristin Moberg Aakre et al. (2009). Monitoring renal Function in Fabry children; estimated or measured glomerular Filtration rate?. (ekstern lenke)
• Camilla Tøndel; Leif Bostad; Liv Marie Lægreid et al. (2008). Prominence of glomerular and vascular changes in renal biopsies in children and adolescents with Fabry disease and microalbuminuria. (ekstern lenke)
• Cathrin Lytomt Salvador; Camilla Tøndel; Lars Mørkrid et al. (2013). GLOMERULAR FILTRATION RATE (GFR) MEASURED BY IOHEXOL CLEARANCE IN CHILDREN; A COMPARISON BETWEEN VENOUS SAMPLES AND DRIED BLOOD SPOTS. (ekstern lenke)

Studieprotokoll

• Bjørn Blomberg; Nikolai Norevik Myklebust; Oddvar Oppegaard et al. (2025). Randomized trial of nirmatrelvir/ritonavir versus placebo for adults with acute COVID-19 to prevent long COVID: PanoramicNOR Trial | Trials | Full Text. (ekstern lenke)

Konferanseforedrag

• Amit Bansal; Mai Chi Trieu; Anders Madsen et al. (2020). Low infection and seroconversion rates in frontline healthcare workers during the peak of the Coronavirus disease 2019 pandemic in Bergen, Norway. (ekstern lenke)
• Amit Bansal; Mai Chi Trieu; Anders Madsen et al. (2020). SARS-COV-2-Specific neutralising antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. (ekstern lenke)
• Amit Bansal; Mai Chi Trieu; Anders Madsen et al. (2020). Antibody responses to SARS-CoV-2 virus in Norwegian health-care workers: an observational prospective cohort study. (ekstern lenke)
• Kristin Greve Isdahl Mohn; Rebecca Jane Cox; Fan Zhou et al. (2015). Cellular immune responses after live attenuated influenza vaccination in children, a clinical trial.. (ekstern lenke)
• Olav H. Haugen; Camilla Tøndel; Einar Svarstad (2009). Corneal changes in Fabry's disease. (ekstern lenke)
• Philipp Strauss; Øystein Solberg Eikrem; Camilla Tøndel et al. (2019). Fabry Nephropathy: First mRNA-seq Findings from Kidney Biopsies Before and After Enzyme Replacement Therapy. (ekstern lenke)
• Camilla Tøndel; Idunn Riisnes; Sabine Leh et al. (2021). Cleared Podocytes and Normal Kidney Function in Classical Fabry Males 15 Years After Start of Enzyme Replacement Therapy at Young Age. (ekstern lenke)
• Camilla Tøndel; Leif Bostad; Einar Svarstad (2010). 5 YEARS FOLLOW-UP RENAL BIOPSIES IN PAEDIATRIC AND ADULT FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY. (ekstern lenke)
• Camilla Tøndel; Einar Svarstad (2013). Podocytes: Therapeutic Target in Fabry Disease?. (ekstern lenke)

Leserbrev

• Bjørn Steinar Demma Lillås; Camilla Tøndel; Toralf Melsom et al. (2023). Response to Birth Weight and Renal Functional Reserve in Adults. (ekstern lenke)
• Sigrid Bratlie; Muath K Alsheikh; Trygve Brautaset et al. (2023). Mer faglighet fra naturbevegelsen, takk. (ekstern lenke)
• Anne Kjørsvik Bertelsen; Camilla Tøndel; Jørgen Gitlesen Krohn et al. (2013). Small fibre neuropathy in Fabry disease. (ekstern lenke)
• Gunnar Houge; Camilla Tøndel; Øyvind Kaarbøe et al. (2011). Fabry or not Fabry – a question of ascertainment. (ekstern lenke)

Vitenskapelig litteraturgjennomgang

• Camilla Tøndel; Beth L. Thurberg; Pronabesh DasMahapatra et al. (2022). Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues. (ekstern lenke)
• Allesandro Burlina; Eva Brand; Derralynn A. Hughes et al. (2023). An expert consensus on the recommendations for the use of biomarkers in Fabry disease. (ekstern lenke)
• Christoph Wanner; Michael Arad; Ralf Baron et al. (2018). European expert consensus statement on therapeutic goals in Fabry disease. (ekstern lenke)

Konferanseposter

• Behzad Najafian; Camilla Tøndel; Einar Svarstad et al. (2015). Podocyte Globotriaosylceramide (GL3) Accumulation in Fabry Disease Is Influenced by Age and Genotype. (ekstern lenke)
• Robert Hopkin; Derralynn A. Hughes; John Bernat et al. (2025). Evaluating the relationship between infusion-related reactions and anti-drug antibody status: Results from 111 patients with Fabry disease treated with pegunigalsidase alfa. (ekstern lenke)
• Rannveig Skrunes; Camilla Tøndel; Kristin Kampevold Larsen et al. (2015). LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) BENEFITS THE GLOMERULI MORE THAN THE VASCULATURE IN YOUNGER FABRY NEPHROPATHY. (ekstern lenke)
• Rannveig Skrunes; Einar Svarstad; Kristin Kampevold Larsen et al. (2015). DIFFERENTIAL KIDNEY EFFECTS OF HIGH AND LOW ENZYME DOSE IN MALE SIBLINGS TREATED FOR 13 YEARS. (ekstern lenke)
• John Bernat; Myrl Holida; Stephen Waldek et al. (2025). Extending the interval between pegunigalsidase alfa infusions in patients with Fabry disease: Five-year interim results from the ongoing BRIGHT51 study. (ekstern lenke)
• Aleš Linhart; Kathy Nicholls; Michael West et al. (2019). Pegunigalsidase alfa for the treatment of Fabry disease - Phase III open label, switch over study from agalsidase alfa - Preliminary results. (ekstern lenke)
• Rannveig Skrunes; Kristin Kampevold Larsen; Sabine Maria Leh et al. (2015). FABRY DISEASE DIAGNOSED IN LIVING DONOR KIDNEY TRANSPLANT BIOPSY. (ekstern lenke)
• Eric Wallace; Ozlem Goker-Alpan; Myrl Holida et al. (2023). First results of a head-to-head trial of pegunigalsidase alfa vs. agalsidase beta in Fabry disease: 2 year results of the phase 3 randomized, double-blind, BALANCE study. (ekstern lenke)
• David Smerkous; Michael Mauer; Camilla Tøndel et al. (2023). Development of an online cloud-based tool for automatic measurement of foot process width (FPW) using deep learning (DL): Applications in assessment of podocyte injury in Fabry disease (FD). (ekstern lenke)
• John Bernat; Myrl Holida; Nicola Longo et al. (2023). Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Two-year interim results from the ongoing phase 3 BRIGHT51 open-label extension study. (ekstern lenke)
• Camilla Tøndel; Eric Wallace; Rossana Rocco et al. (2022). Pharmacokinetic (PK) Results From a Phase 3 Trial to Evaluate Pegunigalsidase Alfa Every 4 Weeks (Q4W) in Patients (Pts) With Fabry Disease Previously Treated With Agalsidase Beta or Agalsidase Alfa. (ekstern lenke)
• Camilla Tøndel; Aleš Linhart; Gabriela Dostalova et al. (2020). Switching from Agalsidase Alfa to Pegunigalsidase Alfa for Treating Fabry Disease: One Year of Treatment Data from Bridge, a Phase 3 Open-Label Study. (ekstern lenke)
• David G Warnock; Eric Wallace; Raphael Schiffman et al. (2019). Analysis of the baseline characteristics of Fabry disease patients screened for the pegunigalsidase alfa Phase III BALANCE study. (ekstern lenke)
• Myrl Holida; John Bernat; Nicola Longo et al. (2019). Once every 4 weeks 2 mg/kg of pegunigalsidase alfa for treating Fabry disease- preliminary result of a phase 3 study. (ekstern lenke)
• Behzad Najafian; Kathleen Nicholls; Michael L West et al. (2023). The spectrum of podocyte injury in later onset (LO) variants of Fabry disease (FD). (ekstern lenke)
• Øystein Solberg Eikrem; Nicolas Delaleu; Philipp Strauss et al. (2020). Systems Analyses of Renal Fabry Transcriptome and Response to Enzyme Replacement Therapy (ERT) Identifies a Cross-Validated and Druggable ERT-Resistant Module. (ekstern lenke)
• Behzad Najafian; Camilla Tøndel; Einar Svarstad et al. (2019). Accumulation of Globotriaosylceramide in Podocytes (PC) in Fabry Nephropathy Is Associated with Progressive PC Loss. (ekstern lenke)
• John S Bradley; Natalia Makieieva; Camilla Tøndel et al. (2021). Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-dose Clinical Trial. (ekstern lenke)
• Nori JL Smeets; E Teunissen; E Teesselink et al. (2020). Diagnosis of AKI using Iohexol in critically ill children and neonates: preliminary results of the HERO study. (ekstern lenke)
• Camilla Tøndel; Kristin M. Aakre; Atle Brun et al. (2008). Formula GFR overestimates Renal Function in Children and Adult Males with Fabry Disease and Stage 1-2 CKD. (ekstern lenke)
• Camilla Tøndel; Bjørn Egil Vikse; Bjarne Magnus Iversen et al. (2008). Renal biopsies in children in Norway 1988-2005: clinical variables, complications and prognosis. (ekstern lenke)
• David G Warnock; Ozlem Goker-Alpan; John Bernat et al. (2023). Pooled analysis of the effect of pegunigalsidase alfa on renal function: Data from 113 patients in the pegunigalsidase alfa clinical trial program. (ekstern lenke)
• Cathrin Lytomt Salvador; Per Tryggve Kjelland Flemmen; Berit Woldseth et al. (2023). Reduced renal function and other factors influence the measured level of glycosaminoglycans (GAGs) and could lead to diagnostic misinterpretation. (ekstern lenke)
• Fu-Pang Chang; Michael Mauer; Alexey Sokolovskiy et al. (2016). Differential response of glomerular parietal epithelial cells and podocytes to enzyme replacement therapy in Fabry nephropathy. (ekstern lenke)
• Behzad Najafian; Camilla Tøndel; Einar Svarstad et al. (2016). Podocyte Hypertrophy and Globotriaosylceramide (GL-3) Accumulation Are Strong Predictors of Podocyte Loss in Enzyme Replacement Therapy Naïve Male Patients with Fabry Disease. (ekstern lenke)
• Aleš Linhart; Kathy Nicholls; Michael West et al. (2019). Prelimenary Results of the Fabry Disease Phase III Open Label Study of Switching from Agalsidase Alfa to Pegunigalsidase Alfa. (ekstern lenke)
• Einar Svarstad; Rannveig Skrunes; Sabine Maria Leh et al. (2017). Simplified Clinical Pre-histologic Scoring Method of Kidney Biopsies in Fabry Disease. (ekstern lenke)
• Myrl Holida; John Bernat; Nicola Longo et al. (2019). New Regimen of Once Every 4 Weeks 2 mg/kg of Pedunigalsidase Alfa for Treating Fabry Disease - Prelimenary Results of a Phase 3 Study. (ekstern lenke)
• Camilla Tøndel; Antonio Pisani; John A. Bernat et al. (2024). Cross-Sectional Analysis of Organ Involvement and Biomarker Levels in Patients With and Without Antidrug Antibodies to Enzyme Replacement Therapies for Fabry Disease. (ekstern lenke)
• Behzad Najafian; Camilla Tøndel; Einar Svarstad et al. (2017). Podocyte globotriaosylceramide (GL-3) content strongly impacts age-dependent podocyte loss in ERT-naïve male Fabry patients. (ekstern lenke)
• Uma Ramaswami; Frits Wijburg; Daniel G Bichet et al. (2017). A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from kidney cells. (ekstern lenke)
• John Kopsidas; Sanne Hofstraat; Jon Salmanton-García et al. (2022). Capacity mapping and building for pediatric vaccine trials across Europe with VACCELERATE’s harmonized assessment tool. (ekstern lenke)
• Uma Ramaswami; Frits Wijburg; Daniel G Bichet et al. (2017). A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from superficial skin capillary endothelium. (ekstern lenke)
• Fabian Braun; Ahmed Abed; Mathias Woidy et al. (2021). Synuclein Alpha Accumulation Drives Lysosomal Dysfunction in Fabry Podocytopathy. (ekstern lenke)
• Behzad Najafian; Camilla Tøndel; Einar Svarstad et al. (2018). Podocyte structural parameters predict glomerular filtration rate (GFR) loss in male patients with classic Fabry disease. (ekstern lenke)
• Camilla Tøndel; Einar Svarstad; Leif Bostad (2009). Renal follow-up biopsies in young male Fabry patients on enzyme replacement therapy. (ekstern lenke)
• John Bernat; Derralynn A. Hughes; Aleš Linhart et al. (2024). Assessment of immunogenicity from the pegunigalsidase alfa clinical trial program: Integrated analysis of de novo and treatment-boosted anti-drug antibodies. (ekstern lenke)
• Derralynn A. Hughes; John Bernat; Aleš Linhart et al. (2024). Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by dosing regimens. (ekstern lenke)
• Ankit Mehta; Eric Wallace; Aleš Linhart et al. (2024). Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by prior enzyme replacement therapy. (ekstern lenke)
• Myrl Holida; John Bernat; Nicola Longo et al. (2022). Safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Results from the phase 3, open-label, BRIGHT study. (ekstern lenke)
• Camilla Tøndel; Takahiro Kanai; Kristin Kampevold Larsen et al. (2014). Five Children with Fabry Disease and Significant Tissue Damage in Renal Biopsies Despite Normal Clinical Renal Parameters. (ekstern lenke)
• Linda van der Tol; L Vogt; S Florquin et al. (2014). Consensus recommendation on Fabry disease diagnosis in adult patients with kidney disease. (ekstern lenke)
• Camilla Tøndel; Cathrin Lytomt Salvador; Karl Ove Hufthammer et al. (2017). Single-point iohexol plasma clearance in children: validation of multiple formulas and sampling times. (ekstern lenke)
• Bjørn Steinar Demma Lillås; Camilla Tøndel; Bjørn Egil Vikse (2020). Low Birth Weigth Is Associated With Lower Measured Glomerular Filtration Rate In Adult Age. (ekstern lenke)
• Behzad Najafian; Aurelio Silvestroni; Alexey Sokolovskiy et al. (2022). Globotriaosylceramide (GL3) accumulation in Fabry podocytes in female patients is progressive with age and associated with podocyte loss and proteinuria. (ekstern lenke)
• Einar Svarstad; Rannveig Skrunes; Einar Skulstad Davidsen et al. (2019). Clinical Consequences of Paired Cardiac and Kidney Biopsies in a Treatment Naive Female Fabry Patient with a Classical Mutation and Minor Clnical Symptoms. (ekstern lenke)
• Camilla Tøndel; Bjørn Johan Bolann; Cathrin Lytomt Salvador et al. (2013). Glomerular filtration rate (GFR) measured by iohexolclearance in children; how many sample points are necessary?. (ekstern lenke)
• Camilla Tøndel; David G Warnock; Ozlem Goker-Alpan et al. (2023). Pooled analysis of the effect of pegunigalsidase alfa on renal function: Data from 113 patients in the pegunigalsidase alfa clinical trial program. (ekstern lenke)
• Bjørn Steinar Demma Lillås; Camilla Tøndel; Anna Gjerde et al. (2019). Measurement of renal functional response using iohexol clearance. (ekstern lenke)
• Camilla Tøndel; AK Bertelsen; Leif Bostad et al. (2008). Fabry disease: Unusual symptoms in two male children treated with lamotrigine and fabrazyme, respectively. (ekstern lenke)
• Cathrin Lytomt Salvador; Alexander D. Rowe; Anna Kristina Bjerre et al. (2016). Glomerular filtration rate (GFR) strongly influences guanidinoacetic acid (GAA) in plasma and urine. (ekstern lenke)
• Behzad Najafian; Michael Mauer; Einar Svarstad et al. (2014). Enzyme Replacement Therapy (ERT) in Fabry Disease (FD) Reduces Podocyte (PC) Globotriaosylceramide (GL3) Content within a Year (yr). (ekstern lenke)
• Camilla Tøndel; Kristin Kampevold Larsen; Rannveig Skrunes et al. (2014). Renal Biopsies after 6-11 Years of Enzyme Replacement Therapy in 9 Young Classic Fabry Disease Patients. (ekstern lenke)
• Hjørdis Thorsteinsdottir; Cathrin Lytomt Salvador; Camilla Tøndel et al. (2016). GDF-15 in plasma and urine as a marker of kidney function in children. (ekstern lenke)
• Aleš Linhart; Gabriela Dostalova; Kathleen Nicholls et al. (2020). Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study. (ekstern lenke)
• Rannveig Skrunes; Kristin Kampevold Larsen; Einar Svarstad et al. (2014). Fabry nephropathy (FN) outcome and the impact of diagnostic kidney biopsies after 10 years enzyme replacement therapy (ERT). (ekstern lenke)
• Cathrin Lytomt Salvador; Camilla Tøndel; Lars Mørkrid et al. (2013). Glomerular Filtration Rate (GFR) measured by Iohexol Clearance in Children; a comparison between venous samples and dried spots. (ekstern lenke)
• Øystein Solberg Eikrem; Philipp Strauss; Miroslav Sekulic et al. (2018). Fabry nephropathy: Transcriptome sequencing of microdissected renal compartments from archival kidney biopsies at baseline, and after 5 & 10 years of enzyme replacement therapy. (ekstern lenke)
• Christoph Wanner; PM Elliot; V Formin et al. (2018). KIDNEY-SPECIFIC THERAPEUTIC GOALS FOR FABRY DISEASE BASED ON EUROPEAN EXPERT CONSENSUS RECOMMENDATIONS AND SYSTEMATIC REVIEW OF PUBLISHED EVIDENCE. (ekstern lenke)
• Camilla Tøndel; Cathrin Lytomt Salvador; Karl Ove Hufthammer et al. (2018). IOHEXOL CLEARANCE IN CHILDREN WITH LOW GFR: COMPARISON OF 24 HOURS SINGLE-POINT GFR AND MULTIPLE-POINT GFR. (ekstern lenke)
• Thea Tislevoll Eide; Atle Brun; Damien Brackman et al. (2018). SINGLE INTRAVENOUS ACCESS FOR MEASUREMENT OF GLOMERULAR FILTRATION RATE IN CHILDREN AFTER MARKER INJECTION. (ekstern lenke)

Doktorgradsavhandling

• Camilla Tøndel (2013). Markers of nephropathy in young Fabry disease patients; role of kidney biopsies and functional measurements. (ekstern lenke)
• Bjørn Steinar Demma Lillås; Camilla Tøndel; Bjørn Egil Vikse et al. (2024). Impact of birth weight on kidney health in middle-aged adults : Results from the Haugesund Low Birth Weight Study. (ekstern lenke)
• Cathrin Lytomt Salvador; Lars Mørkrid; Stein Bergan et al. (2020). Estimation and measurement of glomerular filtration rate in children. (ekstern lenke)
• Rannveig Skrunes; Camilla Tøndel (2017). Hereditary renal disease in the Norwegian population, with a focus on Fabry disease. (ekstern lenke)
• Philipp Strauss; Øystein Solberg Eikrem; Hans Peter Marti et al. (2023). From archival tissues to systems biology: Using transcriptomics to investigate the progression of kidney disease. (ekstern lenke)

Fremhevet artikkel i media

• Sigrid Bratlie; Camilla Tøndel; Muath K Alsheikh et al. (2023). GMO-regler må ikke få stoppe utviklingen av avanserte terapier. (ekstern lenke)
• Espen Gamlund; Muath K Alsheikh; Sigrid Bratlie et al. (2023). Uetisk å la være å satse på genteknologi. (ekstern lenke)
• Sigrid Bratlie; Arne Holst-Jensen; Muath K Alsheikh et al. (2023). På tide å åpne for genteknologi i norsk matproduksjon. (ekstern lenke)

Forskningsrapport

• Anna Wargelius; Muath K Alsheikh; Espen Gamlund et al. (2023). Genteknologi i en bærekraftig fremtid. (ekstern lenke)

Deltakelse i radio eller TV

• Camilla Tøndel (2015). Liv og død-serien; Legemiddelutprøving hos barn. (ekstern lenke)

Rettelse i tidsskrift

• Camilla Tøndel; Bjørn Johan Bolann; Cathrin Lytomt Salvador et al. (2016). Erratum to: Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times (Pediatric Nephrology, (2017), 32, 2, (311-320), 10.1007/s00467-016-3436-z). (ekstern lenke)

Se en fullstendig oversikt over publikasjoner i NVA.

Filter - Nasjonalt vitenarkiv

PubMed

ResearchGate